Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis

The study found a lower risk of gastrointestinal side effects for Prexige compared to ibuprofen and naproxen, but the incidence of serious liver abnormalities was higher for the COX-2 than for the NSAIDs.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet